AI In Life Sciences Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global AI In Life Sciences Market Trends and Insights

FDA RTOR-Enabled AI Biomarker Approvals

The US FDA’s Real-Time Oncology Review has shortened review cycles for AI-enabled biomarkers by up to 40%, allowing oncology programmes to reach market far sooner than under legacy pathways. Successful precedent in oncology broadened to neuro-degenerative and rare-disease indications in 2024, signalling regulator confidence in AI-generated endpoints. Each new approval creates knock-on value because the validated biomarker can be reused across separate pipelines, accelerating overall portfolio productivity. With the FDA establishing the global benchmark, other agencies are already evaluating similar expedited tracks, effectively globalising the opportunity.^{[1]Center for Drug Evaluation and Research, US Food and Drug Administration, “Real-Time Oncology Review Pilot Program,” fda.gov.}

EU Health Data Space Unlocking Federated AI Model Training

Effective January 2025, the European Health Data Space (EHDS) is giving life-sciences developers API-based access to harmonised clinical, genomic and imaging datasets across 27 member states. Crucially, federated-learning rules permit model training without physical data transfer, preserving privacy but eliminating a historic barrier of fragmentation. Forecasts point to EUR 11 billion in ten-year efficiency savings via reduced duplication and faster evidence generation. Early adopters are re-architecting pipelines so that algorithms can learn on-site and update centrally—an approach that turns Europe’s stringent privacy stance into a competitive differentiator for compliant vendors.^{[2]European Commission, “European Health Data Space Factsheet,” ec.europa.eu}

China’s 17th Five-Year Bio-AI Plan Fueling above 200 Pilot Programs

China’s latest national plan earmarks AI-biotech convergence as a strategic pillar. More than 200 pilots span genomics, digital pathology and automated chemistry, underpinned by grants and preferential procurement. Provincial competition for funding is producing dense regional clusters that combine local manufacturing with academic research, reducing reliance on imported software stacks. The policy blueprint targets an incremental USD 25 billion uplift to the domestic health-tech economy and positions Chinese suppliers to export turnkey AI solutions once regulatory equivalence with global norms is demonstrated.^{[3]State Council Information Office of the People’s Republic of China, “14th and 15th Five-Year Plans for Bio-Economy,” gov.cn}

Hyperscaler Partnerships Cutting Compute Cost per Molecule by 70%

Joint engineering initiatives between hyperscalers and drug developers are optimising hardware configurations for molecular simulations, slashing per-molecule compute expense by roughly 70% since 2024. A prime example is NVIDIA’s collaboration with Recursion Pharmaceuticals, pairing customised GPU clusters with graph-based drug-discovery algorithms. Cost efficiency means that libraries of billions of synthetically accessible compounds can be screened in days rather than months, improving hit-rate probabilities and shrinking early-stage timelines. Companies securing preferred access to such infrastructure are winning disproportionate deal flow, as smaller peers struggle with inflated spot prices for scarce GPUs.^{[4]NVIDIA Corporation, “Recursion and NVIDIA Expand Compute Collaboration,” nvidia.com}

EU AI Act Delaying CE-Mark Timelines for Clinical AI Systems

Classifying most clinical algorithms as “high-risk,” the EU AI Act, in force since August 2024, layers additional conformity-assessment audits onto the CE-mark process. Smaller innovators, often venture-backed, are hardest hit because they lack in-house regulatory teams, leading to launch delays estimated at 6–12 months for imaging and decision-support tools. Although large manufacturers can absorb the cost, the bottleneck is temporarily reducing the funnel of European AI devices, which in turn slows downstream data generation needed for algorithm refinement.

Only 6% of Biopharma Data Are FAIR-Compliant

Industry surveys indicate that just 6% of current R&D data satisfy FAIR principles, limiting machine-learning models’ ability to generalise across cohorts. Poor metadata, siloed storage and inconsistent ontologies inflate the data-wrangling phase that precedes model training. Organisations that invested early in knowledge graphs and data-governance offices show materially higher model accuracy, underlining the economic case for quality improvements. Vendors offering automated curation pipelines and ontology alignment stand to benefit as pharma budgets re-balance toward foundational data assets.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Offering: Software Dominates, Services Accelerate

The software component generated 54.60% of the 2025 revenue base, establishing code libraries and algorithm suites as the primary value driver within the AI in life sciences market. Leading platforms analyse omics data, suggest candidate molecules and predict trial enrolment feasibility, embedding directly into pharmaceutical pipelines. Vendors increasingly differentiate through explainability modules that document model lineage for auditors. Services, though representing a smaller slice, are expanding at a 22.15% CAGR across 2026-2031 as clients seek integration specialists who can align AI outputs with regulated workflows. Managed-service contracts that bundle software licences with validation protocols and post-market performance monitoring are gaining traction because they transfer compliance overhead from sponsors to vendors.Hardware, while modest in revenue share, is strategically important. Specialised accelerator boards designed for stochastic differential-equation solvers and high-throughput docking address current GPU supply constraints. Enterprises are adopting mixed infrastructure strategies—on-premise clusters for sensitive data and burst-to-cloud capacity for large screening jobs—to hedge against supply volatility and enforce data-residency rules. The AI in life sciences market size attached to hardware segments is forecast to grow at a mid-teens rate as new semiconductor entrants release domain-specific architectures.

By Deployment Model: Cloud Platforms Enabling Collaboration

Cloud deployments captured 50.55% of spending in 2025, reflecting the sector’s recognition that elastic computing and distributed collaboration outweigh initial security concerns. Hyperscalers now offer health-data-compliant environments with pre-configured audit logs, reducing validation cycles for 21 CFR Part 11 and GDPR. Multi-tenant sandboxing allows academic consortia and biotechs to share de-identified cohorts, accelerating external innovation. Hybrid architectures, however, are becoming the default. Organisations retain ultra-sensitive genomic archives on-premise but run federated analytic workloads in the cloud, improving utilisation rates without sacrificing sovereignty. On-premise solutions, boosted by sovereign-cloud regulations and latency-critical use cases, are projected to deliver a 16.3% CAGR through the period.Persistent data silos remain a barrier: 81% of surveyed firms cite difficulty reconciling EHR, imaging and omics data within a single environment. Consequently, platform vendors are packaging built-in extract-transform-load utilities and ontology mappers. This dynamic supports service-led revenue streams that complement subscription fees from software licences, anchoring long-run renewal rates within the AI in life sciences market.

By Analytics Type: Generative AI Reshaping Discovery

Predictive analytics retained top-line leadership in 2025, underpinned by statistical and machine-learning models that forecast toxicity, patient response and trial enrolment dynamics. Such capabilities are credited with raising Phase II success odds by up to 15 percentage points. Descriptive and prescriptive layers continue to aid data visualisation and operational decisions, particularly within manufacturing quality-control loops. The generative segment, however, is scaling fastest, with some vendors logging 26.1% CAGR to 2031. Deep diffusion models and transformer architectures can propose viable small-molecule libraries guided by multi-objective fitness functions. When linked to automated synthesis robots, discovery cycles compress from quarters to weeks, shifting the bottleneck from idea generation to biological validation. The AI in life sciences market size flowing through generative use cases is projected to account for a rising share of overall software spending.

By Application: Clinical-Trials Optimisation Gaining Momentum

Drug discovery applications accounted for 25.60% of the 2025 revenue pool, driven by AI-enabled target identification across multi-omics datasets. Integration of graph-neural networks with cheminformatic rules has broadened exploration of “undruggable” targets. The AI in life sciences market share for clinical-trials optimisation is poised to climb as the segment grows at a 20.3% CAGR during 2026-2031. Algorithms that mine real-world data to refine inclusion criteria are cutting screen-fail rates, while remote-monitoring wearables feed continuous biomarkers that improve safety signal detection. Pharmaceutical sponsors report potential 70% cost savings when adaptive trial designs further reduce protocol amendments. Imaging-based diagnostics, bioprocess optimisation and personalised-medicine decision support remain sizeable niches, each benefiting as foundational models become increasingly multimodal.

By End User: Pharma Leads, CROs Accelerate

Pharmaceutical and biotechnology enterprises represented 45.40% of spending in 2025 as they embedded AI into R&D, regulatory, manufacturing and commercial operations. Dual strategies are common: internal centres of excellence for proprietary datasets combined with external licensing for frontier algorithms. CROs form the fastest-expanding customer group at an 17.2% CAGR through 2031 because sponsors outsource analytics-heavy tasks to partners already holding multi-sponsor data troves. The AI in life sciences market size tied to CRO contracts is projected to grow as regulatory bodies encourage data standardisation that multiplies cross-study insights. Medical-device manufacturers, academic institutes and payers constitute the balance of demand, collectively driving ecosystem interoperability.

By Technology: Foundation Models Transforming Capabilities

Machine-learning frameworks—gradient-boosting, random forests and classical deep nets—provide the baseline tooling for pattern recognition in structured datasets. NLP now digests clinical narratives, adverse-event reports and regulatory guidance at scale. Computer vision supports high-content screening and histopathology, adding spatial context to molecular predictions. Deep-learning advances have catalysed foundation models that are pre-trained on hundreds of millions of protein sequences or molecular graphs, delivering zero-shot capabilities for new targets. Transfer learning permits rapid fine-tuning, slashing data requirements for niche diseases. Generative architectures constitute the most rapid-growth technology subset: diffusion and variational-autoencoder pipelines that integrate chemical rules and synthesizability constraints can now output bench-ready compounds in silico. Combined with active-learning loops, each experimental assay returns information that the model feeds back into itself, reinforcing a virtuous discovery cycle.

Geography Analysis

North America commanded 48.60% of 2025 global revenue, anchored by a deep venture capital base, favourable reimbursement codes for digital diagnostics and early regulator engagement. The AI in life sciences market size in the US alone is boosted by the FDA’s RTOR programme, which validates AI-enabled biomarkers that become reusable across multiple development programmes. Multistate health-information exchanges enable richer training sets, although interstate privacy rules still complicate data portability. Cloud-service adoption outpaces other regions because HIPAA-aligned blueprints shorten compliance audits, letting mid-tier biotechs leverage hyperscale compute without building in-house clusters.Europe remains the second-largest region, poised to accelerate once the EHDS federated networks scale. Industry consortia linking academic medical centres with pharmaceutical sponsors are piloting privacy-preserving cross-border training, likely to increase the AI in life sciences market share captured by European vendors as they leverage home-market regulatory familiarity. Counterbalancing this momentum, the AI Act’s high-risk classification introduces extra documentation layers that can elongate product cycles. Companies are responding by integrating regulatory checkpoints into agile sprints, a practice that, while lengthening early iterations, reduces late-stage remediation costs.Asia shows the highest growth trajectory at a 21.3% CAGR between 2026-2031. China exploits coordinated industrial policy to fund AI-enabled drug-discovery megaprojects; provincial biotech parks provide tax holidays and access to national-level supercomputing. Japan and South Korea specialise in robotics and automation, yet lingering IP ambiguity for AI-generated molecules creates a licensing risk premium. India’s contract-research ecosystem leverages large English-language medical records, positioning the country as an outsourcing hub for algorithm training and validation. Divergent national rules dictate a country-by-country go-to-market, but the aggregate opportunity is compelling, with localised cloud regions and sovereign-AI initiatives unlocking new datasets previously inaccessible to global players.South America and the Middle East and Africa are smaller today but constitute important frontier segments. Brazil’s national genomics programmes and Saudi Arabia’s genome project are generating population-specific datasets that draw AI developers seeking diversity in training inputs. Governments are allocating innovation grants to attract multinational partnerships, a trend that could raise the regions’ combined market share over the next decade as infrastructure and skills mature.

Regulatory Landscape

Regulation for AI in life sciences is moving toward lifecycle governance, combining medical-product rules with horizontal AI requirements. In the United States, the FDA has formalized approaches for managing iterative model changes through Predetermined Change Control Plans (PCCPs), including final guidance published in December 2024 for AI-enabled device software functions. This supports post-market modifications when changes stay within an approved plan. In April 2026, the FDA also issued a Federal Register request for information to shape a pilot focused on AI-enabled optimization of early-phase clinical trials, reinforcing the use of structured risk-management practices aligned with the NIST AI Risk Management Framework in regulated development workflows.

In Europe, the EU AI Act has been in force since August 2024 and applies alongside MDR/IVDR for many clinical and diagnostic AI systems categorized as high-risk, raising the compliance bar for documentation, conformity assessment, and post-market monitoring. A concrete implementation milestone is the European Commission deadline in February 2026 (Article 72(3)) to adopt implementing acts that establish a template for post-market monitoring plans for high-risk AI systems. In China, the National Medical Products Administration (NMPA) published Implementation Opinions in May 2026 on "Artificial Intelligence + Drug Regulation" to promote deeper AI integration in drug regulation and accelerate modernization, signaling stronger regulatory pull for compliant AI tooling across the product lifecycle.

Value Chain Analysis

The value chain spans (1) data generation and stewardship (EHRs, imaging, omics, real-world data), (2) data engineering and governance (harmonization, ontologies, privacy-preserving access), (3) model development and validation (predictive and generative AI, explainability, audit trails), (4) compute and deployment (cloud, hybrid, on-premise), and (5) downstream execution in discovery, clinical development, and manufacturing operations. A key bottleneck sits upstream: only a small share of biopharma R&D data are FAIR-aligned in current practice, which increases the cost and cycle time of data preparation and limits cross-study generalization. This elevates the role of data platforms, knowledge graphs, and services partners that can operationalize governance and traceability.

Partnerships increasingly connect AI discovery with process development and supply resilience, shifting the chain from standalone software procurement toward integrated programs involving pharma, techbio firms, and CDMOs. Examples include Gilead Sciences and Terray Therapeutics entering a multi-target collaboration in December 2024 that pairs generative AI with high-throughput experimentation, and Veranova partnering with Phorum.AI in May 2024 to deploy generative AI for chemistry and manufacturing optimization. On the manufacturing resilience side, Ginkgo Bioworks secured a USD 29 million ARPA-H contract in April 2025 with multiple partners to develop distributed API manufacturing approaches (cell-free expression). In July 2025, Phlow Corp. and Antheia highlighted an ongoing partnership to bolster onshore production using biosynthesis and continuous flow chemistry, underscoring a growing link between AI-enabled R&D decisions and scalable, compliant manufacturing pathways.

Market Opportunities and Future Outlook

A near-term opportunity is compliance-ready AI that reduces friction across regulated development, especially tooling that operationalizes governance, human oversight, and post-market monitoring for models used in R&D decision-making and clinical workflows. In January 2026, regulators advanced convergence signals through published Good AI Practice guiding principles for drug development. This reinforces demand for vendor capabilities such as data provenance, model-change control, validation packages, and monitoring plans that can be mapped to FDA and EU expectations. It also supports service-led growth around validation, documentation automation, and managed performance monitoring, particularly for organizations running hybrid architectures and federated learning where auditability must span multiple data holders.

A second whitespace is industrial-scale compute and co-innovation models that translate hyperscale acceleration into domain-specific workflows, lowering the barrier for large virtual screening and multimodal foundation-model development. In January 2026, NVIDIA and Eli Lilly announced a five-year, USD 1 billion AI co-innovation lab using BioNeMo and related capabilities, and in April 2026 Novo Nordisk and OpenAI announced a strategic partnership to integrate AI across discovery, manufacturing, and commercial operations, expanding the addressable spend beyond discovery-only pilots. Data-access and federation programs also create a distinct opportunity for vendors that can deploy privacy-preserving analytics across borders. The European Health Data Space becoming effective in January 2025 enables API-based access and federated training across EU member states, which lifts demand for interoperable platforms and governance layers that can operate across heterogeneous clinical, genomic, and imaging sources.